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Abstract 
Background: Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown 
to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and 
anthracycline‑containing regimens. However, no clinical trials have directly compared the efficacy of MCT and HT 
after response to first‑line capecitabine‑based combination chemotherapy (FCCT) in patients with hormone receptor 
(HR)‑positive and human epidermal growth factor receptor 2 (HER2)‑negative breast cancer.
Methods: We retrospectively analyzed the charts of 138 HR‑positive and HER2‑negative MBC patients who were in 
non‑progression status after FCCT and who were treated between 2003 and 2012 at the Cancer Institute and Hospital, 
Chinese Academy of Medical Sciences, in Beijing, China. The median number of first‑line chemotherapy cycles was 6 
(range, 4–8); combined agents included taxanes, vinorelbine, or gemcitabine. Of these 138 patients, 79 received MCT, 
and 59 received HT. Single‑agent capecitabine was administered at a dose of 1250 mg/m2 twice daily for 14 days, 
followed by a 7‑day rest period, repeated every 3 weeks. Of the 59 patients who received HT, 37 received aromatase 
inhibitors (AIs), 8 received selective estrogen receptor modulators (SERMs), and 14 received goserelin plus either AIs or 
SERMs. We then compared the MCT group and HT group in terms of treatment efficacy.
Results: With a median follow‑up of 43 months, patients in the HT group had a much longer TTP than patients in the 
MCT group (13 vs. 8 months, P = 0.011). When TTP was adjusted for age, menopausal status, Karnofsky performance 
status score, disease‑free survival, site of metastasis, number of metastatic sites, and response status after FCCT, 
extended TTP was still observed for patients in the HT group (hazard ratio: 0.63; 95% confidence interval: 0.44–0.93; 
P = 0.020). We also observed a trend of overall survival advantage for patients in the HT group vs. patients in the MCT 
group, but the difference was not significant (43 vs. 37 months, P = 0.400). In addition, patients in the HT group gen‑
erally tolerated the treatment well, whereas patients in the MCT group experienced grades 3–4 adverse events, the 
most frequent of which were hand‑foot syndrome (15.8%) and hematologic abnormalities (7.6%).
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Chinese Journal of Cancer
*Correspondence:  fanyingfy@medmail.com.cn; xubinghe@medmail.
com.cn 
Department of Medical Oncology, Cancer Hospital, Chinese Academy 
of Medical Sciences & Peking Union Medical College, Panjiayuan, 
Chaoyang District, Beijing 100021, P. R. China
Page 2 of 7Chen et al. Chin J Cancer  (2016) 35:39 
Background
The primary goals of metastatic breast cancer (MBC) 
treatment are to palliate symptoms, preserve quality of 
life, delay tumor progression, and extend overall sur-
vival (OS), not to cure the disease. For hormone receptor 
(HR)-positive and human epidermal growth factor recep-
tor 2 (HER2)-negative patients with MBC, chemotherapy 
is needed as first-line treatment when hormonal therapy 
(HT) has been exhausted or symptomatic visceral metas-
tasis is observed. When the disease is controlled by 
chemotherapy, several sequential strategies can be pur-
sued: discontinuing chemotherapy and observing until 
progression; continuing the same therapy; maintain-
ing with a single, mild agent that was used in the initial 
therapy; or switching to other drugs that are presumed to 
be effective. Several trials showed that maintenance com-
bination chemotherapy extended the duration of remis-
sion [1–7], but modest OS benefits were seen in only two 
trials [3, 4], and the optimal duration of treatments was 
not determined. In addition, in most studies, incidence 
of toxicity was significantly increased. In a Korean phase 
III trial (KCSG-BRO7-02), patients in the paclitaxel/
gemcitabine maintenance arm had much longer median 
progression-free survival (PFS) and OS than patients in 
the observation arm (PFS: 7.5 vs. 3.8 months, P = 0.026; 
OS: 32.3 vs. 23.5  months, P  =  0.047) [4]. The results, 
however, were debatable because any treatment regard-
ing to HR status was not allowed in the control group 
after completing six cycles of induced chemotherapy. At 
the same time, the rate of grade 3 or higher neutropenia 
for patients in the maintenance arm was as high as 61%, 
which inevitably resulted in more hospital visits [4]. In 
fact, many clinicians prefer to discontinue chemotherapy 
after 6–8 cycles when the disease enters non-progression 
status. However, it seems inappropriate to just wait for 
tumor progression. Switching to a more tolerable chemo-
therapy, such as monotherapy or antiangiogenic agents, 
might be a better treatment strategy.
Studies have suggested that maintenance monotherapy 
could be a low-toxicity intervention that significantly 
extends time to progression (TTP) and has potential OS 
benefits [8–11]. Since, for many years, anthracyclines 
or taxanes have been a mainstay of adjuvant therapy for 
breast cancer, the National Comprehensive Cancer Net-
work has recommended capecitabine-based chemothera-
pies, such as capecitabine plus taxanes and capecitabine 
plus vinorelbine, as first-line chemotherapy for MBC 
patients after failure of taxanes and anthracycline-contain-
ing regimens and for patients who cannot receive further 
anthracycline therapy. In prospective, randomized phase 
II/III clinical trials, capecitabine monotherapy has shown 
substantial antitumor activity in the first-line treatment of 
patients with MBC. According to reports in the literature, 
patients who received first-line capecitabine monotherapy 
had a median TTP of 6.0–7.9  months [12]. Long-term 
administration of capecitabine is convenient and rela-
tively economical and does not result in cumulative toxic-
ity. It still works well in combination with target therapy 
[12–17]. Therefore, capecitabine is assumed to be a good 
option for maintenance monotherapy after first-line 
capecitabine-based combination chemotherapy (FCCT).
For patients with HR-positive and HER2-negative 
MBC, HT is also an attractive alternative, at least in 
patients with potentially endocrine-responsive diseases 
that have entered non-progression status after first-
line chemotherapy. In several reported studies of HT 
with powerful endocrine agents [aromatase inhibitors 
(AIs) or tamoxifen], the median TTP of patients was 
14.4–18.5 months after previous chemotherapy (first- or 
second-line) [18, 19]. There seemed to be a TTP dispar-
ity between the maintenance capecitabine monotherapy 
(MCT) and HT groups, but we must be cautious that the 
patient populations of the various studies might be com-
pletely different. Previous studies of HT enrolled patients 
with HR-positive MBC exclusively, whereas studies of 
MCT involved the whole population regardless of hor-
mone status. Unquestionably, HR-positive patients have 
a better prognosis than HR-negative patients. Moreover, 
for patients who are recommended first-line chemother-
apy, disease progression is more aggressive than for those 
who adopt first-line HT. This indicates that the popula-
tion who are suggested FCCT may be more likely to 
benefit from chemotherapy. Until now, because no head-
to-head comparisons or retrospective studies have been 
performed between maintenance chemotherapy and HT 
after disease control, no systematic assessment data exist 
on the efficacy of maintenance therapy. Therefore, in the 
present study, we examined HR-positive/HER2-negative 
patients with MBC after response to FCCT, divided them 
into HT and MCT treatment groups, compared the effi-
cacy of distinct treatments, and sought to determine 
which treatment was superior.
Conclusion: For HR‑positive and HER2‑negative MBC patients, HT might be considered a treatment after response to 
FCCT but prior to MCT as a long‑term administration.
Keywords: Hormonal therapy, Maintenance capecitabine monotherapy, First‑line capecitabine‑based combination 
chemotherapy, Metastatic breast cancer
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Patients and methods
Patient selection
We reviewed the charts of patients diagnosed with MBC 
between 2003 and 2012 at the Cancer Hospital & Insti-
tute, Peking Union Medical College, Chinese Academy of 
Medical Sciences, China. Eligibility criteria for this study 
were as follows. (1) Breast cancer patients were confirmed 
as having a primary HR-positive and HER2-negative 
tumor. Estrogen receptor or progesterone receptor was 
considered “positive” when at least 1% of the nuclei was 
stained as determined by immunohistochemical analysis. 
HER2-negative tumors were scored as 0 or +1 by immu-
nohistochemical analysis or scored +2 but the result of 
fluorescence in situ hybridization was negative. (2) Breast 
cancer recurred with measurable metastatic disease. 
Moreover, response to FCCT was evaluated as complete 
response (CR), partial response (PR), stable disease (SD), 
or progressive disease (PD) according to the Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria, ver-
sion 1.0. (3) Combined agents in FCCT included taxanes, 
vinorelbine, or gemcitabine and were administered for at 
least 4 but no more than 8 cycles. (4) The duration of non-
progression status was at least 4 weeks for patients in the 
MCT group after the last cycle of FCCT, or else it was con-
sidered a failure of combination chemotherapy or resist-
ance to capecitabine. (5) Patients’ Karnofsky performance 
status (KPS) scores were ≥70. Key exclusion criteria were 
(1) the presence of brain metastases, (2) the presence of 
immeasurable disease, and (3) the administration of HT in 
the metastatic setting before FCCT. Informed consent was 
obtained from all eligible patients. The follow-up and data 
collection were completed on March 31, 2015.
Treatment and evaluation
Capecitabine was administrated at a dose of 1250 mg/m2 
twice daily on days 1–14 at initiation, followed by a 7-day 
rest period, repeated every three weeks. Dose modifica-
tions were made according to the drug instructions or 
the attending physician’s judgement. Maintenance HT 
included tamoxifen, AIs, or the combination of ovarian 
suppression with AIs or tamoxifen. TTP was defined as 
the interval from the date of administration of mainte-
nance therapy to tumor progression. OS was defined as 
the time between the initiation of maintenance therapy 
to death from any cause, with censoring of the last visit 
date. Additionally, toxicity profiles were assessed and 
graded according to the Common Terminology Criteria 
for Adverse Events, version 3.0. Tumor evaluation was 
performed every 2–3 months according to RECIST 1.0.
Statistical analysis
Clinicopathologic characteristics were compared 
between the two groups by the Chi square test. TTP and 
OS were estimated using the Kaplan–Meier method and 
compared using the log-rank test. Hazard ratios [two-
sided 95% confidence interval (CI)] were calculated with 
unadjusted and adjusted Cox proportional hazards mod-
els for group comparisons. Potential clinical covariates 
were used to investigate the association of the prognos-
tic factors with TTP and OS. In this model, the covari-
ates included age (≤50 or >50 years), menopausal status 
(premenopausal or postmenopausal), KPS score, dura-
tion of disease-free survival (DFS) (≤2 or >2 years), site 
of metastases (viscera or non-viscera), number of metas-
tases (1 or >1), and response after FCCT (CR +  PR or 
SD). P values less than 0.05 were considered statistically 
significant. All statistical analyses were performed using 
SPSS 22.0 software (IBM SPSS, Armonk, NY, USA).
Results
Patient characteristics
A total of 257 HR-positive and HER2-negative MBC 
patients received FCCT, and 174 patients among them 
were under diseases control. Among the 174 patients, 14 
received palliative HT concurrent with FCCT, 16 received 
maintenance combination chemotherapy, 5 underwent 
paclitaxel maintenance therapy, and 1 received gemcit-
abine maintenance therapy. Thus, only 138 patients were 
eligible for further analysis, with 79 in the MCT group 
and 59 in the maintenance HT group. At the initiation of 
maintenance therapy, the median age of the 138 eligible 
patients was 50 years. Almost all the patients (133 of 138) 
received a taxane or anthracycline-containing regimen 
as neoadjuvant or adjuvant therapy, and 122 patients 
received adjuvant endocrine therapy. Median exposure 
to initial FCCT was six cycles (range, 4–8 cycles). In the 
HT group, 37 patients received AIs, 8 received selective 
estrogen receptor modulators (SERMs), and 14 received 
goserelin plus either AIs or SERMs. The baseline char-
acteristics of the patients were balanced (except for an 
imbalance in the number of metastatic sites and response 
status after FCCT) between the two groups (Table 1). The 
percentage of patients with multi-site metastases (72.1% 
and 49.1%, P  =  0.006) or a better response to FCCT 
(59.1% and 47.4%, P  =  0.009) was higher in the MCT 
group than the HT group.
Efficacy assessment of maintenance therapy
With a median 43-month follow-up, 51 of 59 patients in 
the HT group and 72 of 79 patients in the MCT group 
experienced PD. By the cutoff date, the median TTP 
in the HT group was significantly longer than that in 
the MCT group (13 vs. 8  months, P  =  0.011; Fig.  1a). 
Although multi-site metastases or a better response 
(CR + PR) to FCCT were shown in a higher proportion 
of patients in the MCT group compared with those in 
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the HT group, they were not associated with TTP in uni-
variate analyses (Table  2). A secondary analysis adjust-
ing TTP to predefined covariates (including number of 
metastases and response to FCCT) still showed improve-
ment in the HT group (hazard ratio: 0.63; 95% CI, 0.44–
0.93; P = 0.020; Table 3).
Subset analyses of TTP corroborated the primary 
overall analysis. The advantage of HT over MCT was 
maintained across various subgroups. A hazard ratio 
<1 score favored the option of HT (Fig. 1b). Patients in 
postmenopausal status (hazard ratio: 0.64, P  =  0.036), 
with an interval of DFS longer than 2 years (hazard ratio: 
0.49, P = 0.001), and with two or more metastases (haz-
ard ratio: 0.60, P =  0.037) could get benefits from HT. 
Importantly, for patients who got a better response (CR 
or PR) to FCCT, median TTP was still longer in the 
HT group than in the MCT group (hazard ratio: 0.60, 
P = 0.033).
A total of 70 breast cancer-related deaths were 
observed in our study. The median OS of the whole pop-
ulation was 41 months. Similar to TTP, we compared OS 
between the two groups. We observed a trend of gained 
advantage in OS in the HT group compared with the 
MCT group, but the difference in OS was not statistically 
significant between the two groups (43 vs. 37  months, 
P = 0.400; Fig. 2). The same conclusion could be drawn as 
OS was adjusted to predefined potential prognostic fac-
tors in multivariate analysis. Longer DFS (>2 years) was 
indicated as a sole independent prognostic factor of OS 
Table 1 Demographic and  baseline characteristics of  138 
patients with metastatic breast cancer
HT hormonal therapy, MCT maintenance capecitabine monotherapy, KPS 
Karnofsky performance status, HR hormone receptor, ER estrogen receptor, PgR 
progesterone receptor, DFS disease-free survival, CT chemotherapy, FCCT first-
line capecitabine-based combination chemotherapy, CR complete response, PR 
partial response, SD stable disease
a Except for these values, others are presented as the numbers of patients 
followed by the percentages in the parentheses





Age (years)a 0.009 (t test)
Median 49 50
 Range 37–76 34–66
KPS score 0.349
 90–100 46 (78.0) 56 (70.9)
 70–80 13 (22.0) 23 (29.1)
Menopausal status 0.520
 Premenopausal 20 (33.9) 31 (39.2)
 Postmenopausal 39 (66.1) 48 (60.8)
HR status
 ER‑positive 55 (93.2) 73 (92.4) 0.855
 PgR‑positive 51 (86.4) 65 (82.2) 0.509
Adjuvant HT 0.246
 Yes 50 (84.7) 72 (91.1)
 No 9 (15.3) 7 (8.9)
DFS (years) 0.446
 <2 16 (27.1) 17 (21.5)
 ≥2 43 (72.9) 62 (78.5)
 Mediana (months) 44 42 0.178 (t test)
No. of metastases 0.006
 <2 30 (50.9) 22 (27.9)
 ≥2 29 (49.1) 57 (72.1)
Metastatic sites 0.168
 Viscera 32 (54.2) 52 (65.8)
 Non‑viscera 27 (45.8) 27 (34.2)
Prior adjuvant CT
 Anthracycline 54 (91.5) 70 (88.6) 0.749
 Taxanes 32 (54.2) 53 (67.1) 0.170
Response to FCCT 0.009
 CR + PR 28 (47.4) 55 (69.6)
 SD 31 (52.3) 24 (30.4)
Fig. 1 Comparison of time to progression (TTP) between the HT 
group and the MCT group. a Estimation of TTP, censored on the date 
of last assessment. b Forest plot (TTP analysis); HR < 1 favors HT. DFS 
disease‑free survival, FCCT first‑line capecitabine‑based combina‑
tion chemotherapy, KPS Karnofsky performance status, CR complete 
response, PR partial response, SD stable disease, HT hormonal therapy, 
HR hazard ratio, CI confidence interval, MCT maintenance capecit‑
abine monotherapy
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(hazard ratio: 1.78, P = 0.027; data not shown). Explora-
tory analyses on OS were conducted across predefined 
subsets. No significant difference was observed indicat-
ing specific options of maintenance therapy.
Safety and tolerance
In this study, we collected data on severe adverse events. 
During initial FCCT treatment, the most frequently 
recorded grades 3–4 adverse events were hematologic 
abnormality (31.8%), hand-foot syndrome (8.0%), and 
gastrointestinal toxicity (5.0%). During the maintenance 
treatment phase, 15 of 138 patients experienced grade 
3 or worse adverse events. In the MCT group, the most 
frequently recorded grades 3–4 adverse events were 
hand-foot syndrome (15.8%) and hematologic abnormal-
ity (7.6%). HT was generally well tolerated. No grade 3 
or higher gastrointestinal adverse effects were recorded. 
Only one patient changed to another HT due to vaginal 
bleeding.
Table 2 Log-rank analysis of  TTP and  OS in  the 138 
patients who received maintenance therapy
TTP time-to-progression, OS overall survival, KPS Karnofsky performance status, 
CR complete response, PR partial response, SD stable disease, DFS disease-free 
survival, CT chemotherapy, FCCT first-line capecitabine-based combination 
chemotherapy
a Since there were only 36 patients in the group whose KPS score was 70-80, no 
conclusions could be drawn from the log-rank analysis of OS
Variable Median TTP 
(months)
P value Median OS 
(months)
P value
Age (years) 0.516 0.609
 ≤50 10 42
 >50 9 36
Menopausal status 0.306 0.076
 Premenopausal 10 45
 Postmenopausal 10 37
KPS score 0.916 0.039a
 70–80 8 33
 90–100 8 44
DFS (years) 0.670 0.077
 ≤2 10 34
 >2 8 43
No. of metastases 0.081 0.114
 ≤1 14 55
 >1 9 36
Site of metastases
 Viscera 9 0.106 41 0.905
 Non‑viscera 13 42
Response to FCCT 0.883 0.337
 SD 10 41
 CR + PR 10 43
Table 3 Efficacy analysis of time to progression and over-
all survival by  unadjusted and  adjusted Cox proportional 
hazards models
HR hazard ratio, CI confidence interval, HT hormonal therapy, MCT maintenance 
capecitabine monotherapy
a Adjusted to menopausal status, Karnofsky performance status, number of 
metastasis sites, interval of disease-free survival, visceral disease, and response 
to FCCT, which were all predefined in the study protocol
Variable TTP OS
HT vs. MCT HT vs. MCT
Median (months) 13 vs. 8 43 vs. 37
HR by unadjusted Cox regression 0.64 0.82
 95% CI 0.44–0.91 0.50–1.32
 Log‑rank P value 0.011 0.400
HR by adjusteda Cox regression 0.65 0.83
 95% CI 0.43–0.93 0.49–1.37
 P value 0.018 0.450
Fig. 2 Comparison of overall survival between the HT group and 
the MCT group. a Estimation of overall survival, censored on the date 
of last assessment. b Forest plot (OS analysis); HR < 1 favors HT. DFS 
disease‑free survival, FCCT first‑line capecitabine‑based combina‑
tion chemotherapy, KPS Karnofsky performance status, CR complete 
response, PR partial response, SD stable disease, HT hormonal therapy, 
HR hazard ratio, CI confidence interval, MCT maintenance capecit‑
abine monotherapy
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Sequential treatment
By the cutoff date, 7 patients in each group were continu-
ing their maintenance therapy. The remaining 72 patients 
in the MCT group received second- or third-line HT after 
disease progression, whereas only 34 (66.7%) patients 
received capecitabine in their sequential treatments.
Discussion
In this study, we examined HR-positive and HER2-neg-
ative MBC patients after response to FCCT and found 
that the HT group had a much longer TTP than the MCT 
group. The efficacy was prominent regardless of age, 
interval of DFS, menopausal status, KPS score, number 
of metastases, visceral metastases, and response to first-
line chemotherapy. We observed the same trend in OS, 
too. Moreover, HT also demonstrated a better safety pro-
file. Therefore, we found that HT was a better treatment 
option for a subgroup of patients in this setting.
Unquestionably, HT plays an important role in the 
treatment of HR-positive breast cancer. Because HT has 
been shown to be remarkably efficacious in the adjuvant, 
neoadjuvant, and first-line palliative treatment of breast 
cancer, it is widely used in routine clinical practice dur-
ing breaks in palliative chemotherapy for women with 
recurrent or metastatic disease characterized by HR-
positive tumors [20, 21]. When HT is administered long 
term, therapeutic gains are expected due to its efficacy 
and good safety profile. However, we must be cautious 
in administering it to all HR-positive patients. Evidence-
based data are lacking regarding its maintenance after 
disease control by previous chemotherapy. To date, only 
two small prospective trials have investigated the efficacy 
of maintenance HT after previous palliative chemother-
apy. In one study, 90 patients with disease control after 6 
cycles of anthracycline- and ifosfamide-containing regi-
mens were randomized to receive maintenance medroxy-
progesterone acetate (MPA) therapy or placebo. A longer 
median TTP was seen in the MPA arm compared with 
that in the placebo arm (4.9 vs. 3.7  months, P  =  0.02) 
[22]. However, this study was conducted in 1990s, and 
currently MPA is rarely used as first-line endocrine ther-
apy. In a letrozole-based single-arm phase II study, the 
median TTP from the initiation of letrozole after induced 
chemotherapy was as long as 18.5 months [18].
As with other orally administered drugs, capecitabine 
has been extensively evaluated in both pretreatment and 
first-line treatment for breast cancer patients. Adverse 
events are readily managed by dose modification. When 
using capecitabine as first-line treatment for MBC, the 
objective response rate was as high as 30%–36% for 
anthracycline- and/or taxane-resistant MBC [13–16]. Si 
et al. [23] reported that patients who received MCT after 
FCCT had a median TTP as long as 9.4 months, which 
is superior to the 4.5 months reported in the observation 
arm. Clinicians may prefer MCT in practice, expecting 
sustainability of its good response to FCCT regardless of 
HR status.
In our study, the survival results of each group were 
similar to those previously reported, which justified the 
option of HT for patients with HR-positive and HER2-
negative MBC after response to FCCT. To our knowledge, 
ours is the first study to directly compare the efficacy of 
MCT with that of HT in this subgroup of patients. Our 
study did, however, have some limitations, mainly that it 
had a small sample size and was retrospective in nature, 
so it is not possible to conclusively say that HT contrib-
uted to extended TTP. Since most tumors develop resist-
ance to endocrine therapies after two or three endocrine 
regimens, the effectiveness of these agents in later-line 
settings is limited. As reported in the literature, in most 
studies the median TTP of patients who underwent 
endocrine therapy as second-line or further treatment 
was 3–6 months [10], similar to that of whom underwent 
MCT in later lines [24]. Interestingly, in our study we 
observed a patient who maintained MCT for 41 months 
without progression after PR to FCCT. Therefore, we 
speculate that MCT may also be an appropriate option 
for a small subgroup of patients with HR-positive breast 
cancer and may be more effective in later settings. How-
ever, this warrants additional phase III clinical trials.
Currently, investigators trying to overcome endocrine 
resistance are studying many targeted agents, some of 
which have been found to be effective in the treatment of 
HR-positive MBC, including everolimus, cyclin-depend-
ent kinase 4/6 inhibitors, and histone deacetylase inhibi-
tors [25]. In a relatively short period of time, options for 
maintenance HT after previous chemotherapy will be 
more varied and powerful.
Conclusion
We conclude that maintenance HT may be considered 
prior to administration of capecitabine after response to 
FCCT for patients with HR-positive and HER2-negative 
MBC.
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